GRCE

Grace Therapeutics, Inc. (GRCE) - 10-K Summary

Business Context and Reporting Period

Company: Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2026
Business Overview: A clinical-stage biopharmaceutical company focused on developing novel drug delivery technologies for rare and orphan diseases. The company operates a single segment focused on the development and commercialization of pharmaceutical applications. Following a strategic realignment in May 2023 and a domestication to Delaware in October 2024, the company has concentrated resources on its lead candidate, GTx-104.

Key Financial Metrics

Note: The company has no revenue and operates at a loss. Margins are not applicable.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by $1.8 million (18.5%) primarily due to a $7.1 million reduction in R&D expenses and a $2.3 million decrease in the change in fair value of derivative warrant liabilities.
• R&D Expense Decline: R&D expenses dropped significantly from $9.5 million to $2.4 million. This was driven by the close-out of the pivotal Phase 3 STRIVE-ON trial for GTx-104 in the first quarter of 2026.
• Increased G&A Expenses: General and administrative expenses increased by $1.5 million, largely due to non-recurring legal and due diligence costs related to strategic initiatives and pre-commercial planning for GTx-104.
• Warrant Liability Settlement: The derivative warrant liability balance was reduced to zero following the expiration of 2023 Common Warrants in October 2025, which occurred 60 days after the FDA accepted the GTx-104 NDA for review.
• Cash Position: Cash and cash equivalents decreased by approximately $5.2 million, reflecting operating cash burn partially offset by $4.0 million in proceeds from warrant exercises.

Guidance, Outlook, Risks, and Unusual Items

Regulatory Status (GTx-104):

• In April 2026, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for GTx-104 (nimodipine IV for aSAH).
• The CRL cited deficiencies in Chemistry, Manufacturing, and Controls (CMC), non-clinical toxicology risk assessments, and current Good Manufacturing Practice (cGMP) issues at the company's Contract Manufacturing Organization (CMO).
• The CRL did not raise issues regarding the safety or efficacy of GTx-104. A Type A meeting with the FDA is scheduled to clarify the path forward.

Strategic Shifts & Impairments:

• In June 2026, the Board decided not to resume internal development funding for de-prioritized candidates GTx-102 (Ataxia Telangiectasia) and GTx-101 (Postherpetic Neuralgia).
• Unusual Item: The company expects to recognize a non-cash impairment charge of approximately $13.5 million ($9.2 million for GTx-102 and $4.3 million for GTx-101) in the first quarter of fiscal year 2027.

Liquidity and Capital Resources:

• As of March 31, 2026, the company held $17.0 million in cash.
• Management believes existing cash is sufficient to fund operations for at least 12 months from the issuance date of the financial statements.
• Additional capital will be required for commercial launch (if approved) and to address CRL deficiencies. The company plans to raise funds through equity offerings, debt, or strategic partnerships.

Risks:

• Regulatory Risk: Failure to resolve CRL deficiencies could delay or prevent approval of GTx-104.
• Manufacturing Risk: Dependence on a third-party CMO that has cited cGMP deficiencies.
• Going Concern: The company has incurred losses since inception and requires additional financing to continue operations beyond the 12-month horizon.

Key Facts for Investor Verification

• CRL Resolution Timeline: Verify the outcome of the scheduled Type A meeting with the FDA and the estimated timeline/cost to remediate the CMC and cGMP deficiencies cited in the April 2026 CRL.
• Impairment Charge Timing: Confirm the exact timing and accounting treatment of the expected $13.5 million impairment charge for GTx-101 and GTx-102 in Q1 FY2027.
• CMO Status: Assess the progress of the current Contract Manufacturing Organization in resolving the cGMP deficiencies and the contingency plan if a new manufacturer is required.
• Cash Runway: Monitor quarterly cash burn rates to validate the 12-month liquidity runway, especially given the pause in commercialization spending pending regulatory resolution.
• Warrant Expirations: Note that 2023 Common Warrants expired in October 2025, but 2025 Common Warrants remain outstanding and expire upon FDA approval of GTx-104 or September 25, 2028, whichever is earlier.